Alpha 2.0
Login Register
» Authors » Peter Beitsch

Peter Beitsch

Explore the profile of Peter Beitsch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 1486
Followers 0
Related Specialties
Oncology
General Surgery
Radiology
Top 10 Co-Authors
Pat Whitworth
Martin Keisch
Maureen Lyden
Frank A Vicini
Chirag Shah
Frank Vicini
Mark Gittleman
Coral Quiet
Peter Blumencranz
Sukamal Saha
Published In
Ann Surg Oncol
Int J Radiat Oncol Biol Phys
Am J Surg
J Clin Oncol
Brachytherapy
Affiliations
Soon will be listed here.
Recent Articles
1.
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine-Biology Is Still King
Layeequr Rahman R, Santillan A, Habibi M, Beitsch P, Whitworth P, Ramaswamy H, et al.
Int J Mol Sci . 2025 Jan; 26(2. PMID: 39859207
Clinical T3 (cT3) breast cancer (BC) presents a challenge for achieving cosmetically acceptable breast conservation, and neoadjuvant chemotherapy (NAC) is commonly used for cytoreduction in these high-risk cancers. MammaPrint risk-of-recurrence...
2.
Cascade testing for hereditary cancer: comprehensive multigene panels identify unexpected actionable findings in relatives
Heald B, Pirzadeh-Miller S, Ellsworth R, Nielsen S, Russell E, Beitsch P, et al.
J Natl Cancer Inst . 2023 Sep; 116(2):334-337. PMID: 37756683
Current guidelines recommend single variant testing in relatives of patients with known pathogenic or likely pathogenic germline variants in cancer predisposition genes. This approach may preclude the use of risk-reducing...
3.
Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial
Hwang E, Beitsch P, Blumencranz P, Carr D, Chagpar A, Clark L, et al.
JAMA Surg . 2022 May; 157(7):573-580. PMID: 35544130
Importance: Positive margins following breast-conserving surgery (BCS) are often identified on standard pathology evaluation. Intraoperative assessment of the lumpectomy cavity has the potential to reduce residual disease or reexcision rate...
4.
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Slingluff C, Lewis K, Andtbacka R, Hyngstrom J, Milhem M, Markovic S, et al.
J Immunother Cancer . 2021 Oct; 9(10). PMID: 34599031
Background: Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing...
5.
Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID‑19 pandemic. The COVID‑19 pandemic breast cancer consortium"
Beitsch P, Whitworth P, Patel R
Breast Cancer Res Treat . 2020 May; 182(2):511-512. PMID: 32451680
No abstract available.
6.
Reply to M.S. Copur et al, A. Taylor et al, and P.S. Rajagopal et al
Beitsch P, Hughes K, Whitworth P
J Clin Oncol . 2019 Jun; 37(24):2178-2180. PMID: 31246521
No abstract available.
7.
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
Groenendijk F, Treece T, Yoder E, Baron P, Beitsch P, Audeh W, et al.
NPJ Breast Cancer . 2019 Apr; 5:15. PMID: 31016233
Immunohistochemically ER-positive HER2-negative (ER+HER2-) breast cancers are classified clinically as Luminal-type. We showed previously that molecular subtyping using the 80-gene signature (80-GS) reclassified a subset of ER+HER2- tumors to molecular...
8.
Guidelines Do Not Proscribe Surgeons Performing Genetic Testing
Hughes K, Beitsch P, Chen S
JAMA Surg . 2018 Dec; 154(3):269. PMID: 30540356
No abstract available.
9.
Evidence based outcomes of the American Society of Breast Surgeons Nipple Sparing Mastectomy Registry
Mitchell S, Willey S, Beitsch P, Feldman S
Gland Surg . 2018 Jul; 7(3):247-257. PMID: 29998074
Background: The American Society of Breast Surgeons (ASBrS) Nipple Sparing Mastectomy Registry (NSMR) is a prospective, non-randomized, IRB approved, multi-institutional registry. The purpose of this Registry is to provide a...
10.
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Beitsch P, Whitworth P, Baron P, Rotkis M, Mislowsky A, Richards P, et al.
Ann Surg Oncol . 2017 Apr; 24(9):2539-2546. PMID: 28447218
Background: Pertuzumab became a standard part of neoadjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancers approximately halfway through Neoadjuvant Breast Registry Symphony Trial (NBRST) enrollment, providing...